Summit Session Highlight
"Active Surveillance - To Treat or Not to Treat Prostate Cancer"
Friday, September 20th | 8:30 am - 12:00 pm
Summit Venue: Biotechnology Industry Organization
1201 Maryland Ave., SW | Suite 900 | Washington, DC 20024
About the Session:
Delaying the immediate treatment of prostate cancer through active surveillance has gained increased support from medical experts. This session will present the concept of active surveillance, the scientific evidence supporting it and the known benefits and risks for patients. The session will also examine how this treatment option may apply to African American patients.
Featured Session Speakers
Professor of Urology, Oncology, Johns Hopkins Medicine
Director, Division of Adult Urology, Brady Urological Institute
Dr. Carter runs the Active Surveillance program for prostate cancer at Johns Hopkins. He pioneered the concept of PSA rate of change (PSA velocity) as a marker of prostate cancer presence to predict the behavior of prostate cancer . He was the first to publish data demonstrating that an individual's personal prostate cancer screening program should be tailored to baseline PSA levels performed at an early age instead of using a "one size fits all" approach.
Director International Urology
Co-Director Prostate Cancer Multi-Disciplinary Clinic
Johns Hopkins Medical Institutions